Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.
Standard pembrolizumab plus lenvatinib remains the best first-line option for advanced kidney cancer, as adding other drugs didn't improve outcomes.
Pembrolizumab plus lenvatinib is a first-line standard of care for advanced clear-cell renal-cell carcinoma (ccRCC). Neither addition of the HIF-2α inhibitor belzutifan nor the CTLA-4 inhibitor quavonlimab to pembrolizumab plus lenvatinib improved outcomes in participants with previously untreated advanced RCC versus pembrolizumab and lenvatinib alone.
What the study was
- Study design
- Randomized phase 3 clinical trial
- Population
- The phase 3 LITESPARK-012 study (NCT04736706) evaluated efficacy and safety of adding belzutifan (HIF-2α inhibitor) or quavonlimab (anti-CTLA-4) to this regimen.
- Sample size
- 560
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Ann Oncol
Why it surfaced
Randomized phase 3 clinical trial with a PubMed abstract reviewed; the 9/10 score reflects conservative novelty, relevance, design-quality, and population/unmet-need assessment.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.